Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

Expert continues discussion of IDH1 and IDH2 inhibitors in AML and examines prioritization of IDH1 and IDH2 inhibitors versus venetoclax in newly diagnosed AML.

Related Content:

Targeted Therapy Treatment Innovations in AMLHematology

BMY, 2seventy’s Abecma Demonstrates Positive Results for Treatment of Multiple Myeloma

FDA Approves Acalabrutinib Tablet Formulation for All Approved Indications

FDA Accepts BLA for Omidubicel for Individuals Who Need Bone Marrow Transplants